Welcome To Diurnal

Diurnal is a UK-based specialty pharmaceutical company dedicated to developing hormone therapeutics to aid lifelong treatment for rare and chronic endocrine conditions, including Congenital Adrenal Hyperplasia, Adrenal Insufficiency, Hypogonadism and Hypothyroidism.

The company has a strong, multi-skilled entrepreneurial management team with extensive pharmaceutical product development experience and an affiliated network of world-class clinical experts in the area of endocrinology.

Mission Statement

To address the major unmet clinical and patient needs in endocrinology by creating products for the lifelong treatment of chronic conditions.

Latest News

  • 01 Apr
    2020

    Diurnal’s European Marketing Authorisation Application for Chronocort® passes validation stage with EMA

    European regulatory recommendation for approval targeted for Q1 2021

    Read More

  • 27 Mar
    2020

    US licencing agreement with Eton Pharmaceuticals for Alkindi® Sprinkle

    Diurnal partners with specialist in hospital and paediatric-focused products
    Total up-front payment and future milestones of up to $52.5 million

    Read More

  • 13 Feb
    2020

    US FDA Accepts for Review Diurnal’s New Drug Application for Alkindi® Sprinkle

     

    Read More